Sort
51,570 grants matching “autoimmune disease”
Role of NKG2 Family Receptors in Regulating the Immune Response
$996,998John E Coligan · Niaid Extramural Activities · Z01 · FY2007 · AI
Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects
$996,926Jeffrey S King · Virogenomics Biodevelopment, Inc. · R44 · FY2021 · AI
Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects
$996,486Renee Lynn Shirley · Virogenomics Biodevelopment, Inc. · R44 · FY2022 · AI
XT-101: A Novel and Potent Non-Opioid Treatment for Neuropathic Pain
$996,485Raymond A. Chavez · Xalud Therapeutics, Inc. · U44 · FY2012 · NS
Immunomodulatory Therapy for Neuropathic Pain
$996,399Ridong Chen · Apt Therapeutics, Inc. · R44 · FY2021 · NS
Targeting leukocyte metabolism to treat human autoimmune disease
$996,128Jay L Rothstein · Immunext, Inc. · R44 · FY2019 · AI
Role of the microbiota in regulating the mononuclear phagocyte system
$996,061Silvana Goldszmid · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Safe and Efficacious Oral MIF Inhibitors for Rheumatoid Arthritis
$995,900Anderson Gaweco · Innovimmune Biotherapeutics Holding, Llc · R44 · FY2014 · AI
Safe and Efficacious Oral MIF Inhibitors for Rheumatoid Arthritis
$995,900Anderson Gaweco · Innovimmune Biotherapeutics Holding, Llc · R44 · FY2015 · AI
Safe and Efficacious Oral MIF Inhibitors for Rheumatoid Arthritis
$995,900Anderson Gaweco · Innovimmune Biotherapeutics Holding, Llc · R44 · FY2016 · AI
R-5280, A Novel Modified Superior Resistant Starch Therapy for Type 1 Diabetes
$995,869Christian Furlan Freguia · Rise Therapeutics, Llc · R44 · FY2024 · DK
Targeting leukocyte metabolism to treat human autoimmune disease
$995,802Jay L Rothstein · Immunext, Inc. · R44 · FY2018 · AI
Targeting leukocyte metabolism to treat human autoimmune disease
$995,802Jay L Rothstein · Immunext, Inc. · R44 · FY2020 · AI
Monoclonal Antibodies for Alzheimer's Immunotherapy
$995,765Andrew C Hiatt · Mapp Biopharmaceutical, Inc. · R44 · FY2009 · AG
ImmGen: a gene expression compendium for immune cells
$995,309Christophe O Benoist · Joslin Diabetes Center · R24 · FY2008 · AI
Colorado AMC REACH Hub
$995,236Richard C Duke · University Of Colorado Denver · U01 · FY2020 · HL
Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease
$995,160Matthew F. Mackey · Immunext, Inc. · R42 · FY2014 · AI
Molecular Mechanisms and Genetics of Autoimmunity
$995,065Patrick M Gaffney · Oklahoma Medical Research Foundation · P20 · FY2009 · RR
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus
$994,978Kenneth Schultz · Trethera Corporation · R44 · FY2025 · AI
IMMUNOGENETICS OF DEMYELINATION
$994,535Mayo Clinic Coll Of Medicine, Rochester · P01 · FY2002 · NS
i-AKC: Integrated AIRR Knowledge Commons
$994,460Lindsay G. Cowell · Ut Southwestern Medical Center · U24 · FY2024 · AI
SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia
$994,448Michael Arthur Bruckman · Haima Therapeutics, Llc · R44 · FY2023 · HL
Sociodemographic Disparities in SLE Incidence: Behavioral and Psychosocial Factors
$994,269Karen H Costenbader · Brigham And Women'S Hospital · R01 · FY2017 · AR
A Novel IL-35 Expressing Probiotic Platform for Inducing Allergen Specific Tolerance
$994,179Neil A Fanger · Virtici, Llc · R44 · FY2021 · AI
Biologic correlatives of chronic GVHD onset
$993,954Stephanie J Lee · Fred Hutchinson Cancer Research Center · U01 · FY2019 · CA